Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 13/20 | 0.51 |
| ▸ | NPC1 | O15118 | 12/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31286473 | 0.79 | KDM4E (0.36) | PTGS1PTGS2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL31731985 | 0.77 | RAB9A (0.67) | PTGS1PTGS2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL28648562 | 0.76 | PTGS1 (0.50) | PTGS1PTGS2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL13325739 | 0.76 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL6391395 | 0.76 | RAB9A (0.71) | PTGS1PTGS2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2079932 | 0.76 | PTGS1 (0.58) | PTGS1PTGS2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3313092 | 0.76 | RAB9A (0.65) | PTGS1PTGS2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL19153502 | 0.76 | NPC1 (0.37) | PTGS1PTGS2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL794230 | 0.74 | RAB9A (0.58) | PTGS1PTGS2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL755953 | 0.74 | RAB9A (0.58) | PTGS1PTGS2RAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492193-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | FONDAZIONE INSTITUTO ITALIANO DI TECNOLOGIA (IT) | 2025-12-09 | — | — | US | claimed |
| EP-3644991-B1 | 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME LLC (US) | 2023-08-02 | — | — | EP | claimed |
| US-20230212157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | ISTITUTO GIANNINA GASLINI (IT) | 2023-07-06 | — | — | US | claimed |
| US-11597723-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | FONDAZIONE ISTITUTO ITALIANO DI TECHNOLOGIA (IT) | 2023-03-07 | — | — | US | claimed |
| CN-115369430-A | Synthetic method of 3-aminomethyl imidazo [1,2-a ] pyridine derivative | 深圳职业技术学院 | 2022-11-22 | — | — | CN | claimed |
| CN-113372346-B | Synthetic method of 3-fatty amine methyl imidazo [1, 2-alpha ] pyridine compound | 南华大学 | 2022-08-19 | — | — | CN | claimed |
| EP-2734516-B1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BOEHRINGER INGELHEIM INT (DE) | 2015-06-17 | — | — | EP | claimed |
| EP-2155751-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | AstraZeneca AB (SE) | 2010-02-24 | — | — | EP | claimed |
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | claimed |
| EP-1569936-B1 | NOVEL SUBSTITUTED IMIDAZO-PYRIDINONES AND IMIDAZO-PYRIDAZEIONES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-03-18 | — | — | EP | claimed |
| WO-2008136756-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | WO | claimed |
| US-7109192-B2 | Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2006-09-19 | — | — | US | claimed |
| US-20050020574-A1 | New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2005-01-27 | — | — | US | claimed |
| EP-0499521-B1 | Inhibitors of N-myristoyltransferase, their preparation process and pharmaceutical compositions containing them | ADIR (FR) | 1995-06-14 | — | — | EP | claimed |
| EP-0204285-A1 | Imidazoheterocyclic compounds processes for preparation thereof and pharmaceutical compositions comprising them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-12-10 | — | — | EP | claimed |
| US-12583870-B2 | Azaheteroaryl compound and application thereof | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2026-03-24 | — | — | US | disclosed |
| US-12577226-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-0144101-A2 | Bicyclic heterocyclyl containing N-(bicyclic heterocyclyl)-4-piperidinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-06-12 | — | — | EP | disclosed |
| EP-0054858-B1 | ACID AZODYESTUFFS WITH IMIDAZOPYRIDINE COUPLING COMPONENTS, THEIR PREPARATION AND USE IN DYEING OF POLYAMID FIBRES | BAYER AG (DE) | 1984-07-11 | — | — | EP | disclosed |
| EP-0054858-A1 | Acid azodyestuffs with imidazopyridine coupling components, their preparation and use in dyeing of polyamid fibres | BAYER AG (DE) | 1982-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099195-A1 | Therapeutic Compounds 570 | OPRL1, OPRK1, OPRM1 | PTGS1 197/4885PTGS2 654/4885RAB9A 939/4885 |
| US-20230212157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCC5, ABCC1 | PTGS1 2381/4885PTGS2 2931/4885RAB9A 1996/4885 |
| US-12583870-B2 | Azaheteroaryl compound and application thereof | NR3C1, EED, EZH2 | PTGS1 3588/4885PTGS2 4392/4885RAB9A 467/4885 |
| US-20050020574-A1 | New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | PTGS1 2409/4885PTGS2 3402/4885RAB9A 3603/4885 |
| US-12577226-B2 | Compounds for treating Huntington's disease | HTT, HYPK, GRIN2C | PTGS1 2253/4885PTGS2 2970/4885RAB9A 1740/4885 |
| US-12492193-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | CFTR, ABCC5, ABCC1 | PTGS1 2381/4885PTGS2 2931/4885RAB9A 1996/4885 |
| US-11597723-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | CFTR, ABCC5, ABCC3 | PTGS1 2397/4885PTGS2 2979/4885RAB9A 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.